Published in J Biol Chem on February 01, 2010
STIM proteins: dynamic calcium signal transducers. Nat Rev Mol Cell Biol (2012) 2.90
A novel native store-operated calcium channel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells. J Biol Chem (2010) 1.67
Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients. PLoS One (2012) 1.18
Wilms tumor protein recognizes 5-carboxylcytosine within a specific DNA sequence. Genes Dev (2014) 1.02
STIM1 is required for attenuation of PMCA-mediated Ca2+ clearance during T-cell activation. EMBO J (2012) 1.01
Transcriptional mechanisms regulating Ca(2+) homeostasis. Cell Calcium (2010) 0.90
Ca2+-dependent transcriptional control of Ca2+ homeostasis. J Biol Chem (2012) 0.88
Orais and STIMs: physiological mechanisms and disease. J Cell Mol Med (2012) 0.87
Multifaceted roles of STIM proteins. Pflugers Arch (2013) 0.85
Alternative splicing converts STIM2 from an activator to an inhibitor of store-operated calcium channels. J Cell Biol (2015) 0.85
WT1/EGR1-mediated control of STIM1 expression and function in cancer cells. Front Biosci (Landmark Ed) (2011) 0.82
The critical role of STIM1-dependent Ca2+ signalling during T-cell development and activation. Int J Biochem Cell Biol (2013) 0.77
STIM1 plays an important role in TGF-β-induced suppression of breast cancer cell proliferation. Oncotarget (2016) 0.77
The role of ion channels in the hypoxia-induced aggressiveness of glioblastoma. Front Cell Neurosci (2015) 0.77
Novel STIM1-dependent control of Ca2+ clearance regulates NFAT activity during T-cell activation. FASEB J (2016) 0.76
Discovery and structural optimization of 1-phenyl-3-(1-phenylethyl)urea derivatives as novel inhibitors of CRAC channel. Acta Pharmacol Sin (2015) 0.75
A new role for wilms tumor protein 1: differential activities of + KTS and -KTS variants to regulate LHβ transcription. PLoS One (2015) 0.75
Orai1 Expression Is Closely Related with Favorable Prognostic Factors in Clear Cell Renal Cell Carcinoma. J Korean Med Sci (2016) 0.75
Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol (2003) 18.97
A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature (2006) 14.78
STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx. Curr Biol (2005) 14.53
STIM1, an essential and conserved component of store-operated Ca2+ channel function. J Cell Biol (2005) 13.11
CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. Science (2006) 9.61
Genome-wide RNAi screen of Ca(2+) influx identifies genes that regulate Ca(2+) release-activated Ca(2+) channel activity. Proc Natl Acad Sci U S A (2006) 7.26
WT-1 is required for early kidney development. Cell (1993) 7.05
A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell (1988) 6.62
Requirement of the inositol trisphosphate receptor for activation of store-operated Ca2+ channels. Science (2000) 5.04
The cellular and molecular basis of store-operated calcium entry. Nat Cell Biol (2002) 3.40
Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell (2009) 3.20
Stim1 and Orai1 mediate CRAC currents and store-operated calcium entry important for endothelial cell proliferation. Circ Res (2008) 2.60
Hair loss and defective T- and B-cell function in mice lacking ORAI1. Mol Cell Biol (2008) 2.50
STIM2 is an inhibitor of STIM1-mediated store-operated Ca2+ Entry. Curr Biol (2006) 2.38
Evidence for STIM1- and Orai1-dependent store-operated calcium influx through ICRAC in vascular smooth muscle cells: role in proliferation and migration. FASEB J (2009) 2.36
GOK: a gene at 11p15 involved in rhabdomyosarcoma and rhabdoid tumor development. Cancer Res (1997) 2.11
Growth and differentiation proceeds normally in cells deficient in the immediate early gene NGFI-A. J Biol Chem (1995) 1.77
Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res (2001) 1.73
Role of endogenous TRPC6 channels in Ca2+ signal generation in A7r5 smooth muscle cells. J Biol Chem (2005) 1.69
A clinical overview of WT1 gene mutations. Hum Mutat (1997) 1.67
Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia (1992) 1.60
STIM and Orai: dynamic intermembrane coupling to control cellular calcium signals. J Biol Chem (2009) 1.59
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res (2006) 1.58
Capacitative calcium entry and transient receptor potential canonical 6 expression control human hepatoma cell proliferation. Hepatology (2008) 1.49
Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res (2005) 1.48
The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem (1992) 1.41
The short N-terminal domains of STIM1 and STIM2 control the activation kinetics of Orai1 channels. J Biol Chem (2009) 1.37
Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. Oncogene (2003) 1.33
Comparison of the DNA binding characteristics of the related zinc finger proteins WT1 and EGR1. Biochemistry (1998) 1.33
New insights into the molecular mechanisms of store-operated Ca2+ signaling in T cells. Trends Mol Med (2007) 1.31
Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol (1994) 1.27
STIM1- and Orai1-dependent store-operated calcium entry regulates human myoblast differentiation. J Biol Chem (2008) 1.25
Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem (1993) 1.16
The G401 cell line, utilized for studies of chromosomal changes in Wilms' tumor, is derived from a rhabdoid tumor of the kidney. Am J Pathol (1993) 1.12
Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs (2007) 1.06
Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors. Cancer Sci (2004) 1.02
Exon structure and promoter identification of STIM1 (alias GOK), a human gene causing growth arrest of the human tumor cell lines G401 and RD. Cytogenet Cell Genet (1999) 1.02
Expression of WT1 protein in fetal kidneys and Wilms tumors. Lab Invest (1994) 0.99
Calcium-mediated signal transduction: biology, biochemistry, and therapy. Cancer Metastasis Rev (1994) 0.92
Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma. Clin Cancer Res (2000) 0.90
Sensitivity of myeloid leukemia cells to calcium influx blockade: application to bone marrow purging. Exp Hematol (2002) 0.84
Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues. Cancer Chemother Pharmacol (1994) 0.84
The WT1 Wilms' tumor suppressor gene is a downstream target for insulin-like growth factor-I (IGF-I) action in PC12 cells. J Neurochem (2006) 0.79
Phorbol myristate acetate-induced Egr-1 expression is suppressed by phospholipase D isozymes in human glioma cells. FEBS Lett (2007) 0.77
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
CRACM1 multimers form the ion-selective pore of the CRAC channel. Curr Biol (2006) 6.02
STIM1 has a plasma membrane role in the activation of store-operated Ca(2+) channels. Proc Natl Acad Sci U S A (2006) 3.32
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
Dynamic assembly of TRPC1-STIM1-Orai1 ternary complex is involved in store-operated calcium influx. Evidence for similarities in store-operated and calcium release-activated calcium channel components. J Biol Chem (2007) 2.63
Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc (2007) 2.54
The calcium store sensor, STIM1, reciprocally controls Orai and CaV1.2 channels. Science (2010) 2.46
TPC proteins are phosphoinositide- activated sodium-selective ion channels in endosomes and lysosomes. Cell (2012) 2.35
Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther (2003) 2.31
A common mechanism underlies stretch activation and receptor activation of TRPC6 channels. Proc Natl Acad Sci U S A (2006) 2.30
mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell (2010) 2.27
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25
Acetylcholinesterase inhibitors from plants. Phytomedicine (2007) 2.25
Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol (2003) 2.24
Leads from Indian medicinal plants with hypoglycemic potentials. J Ethnopharmacol (2006) 2.21
Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12
Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell (2004) 1.91
IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta (2006) 1.88
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol (2005) 1.85
Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell (2003) 1.84
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res (2005) 1.83
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res (2009) 1.79
S-glutathionylation activates STIM1 and alters mitochondrial homeostasis. J Cell Biol (2010) 1.77
STIM2 protein mediates distinct store-dependent and store-independent modes of CRAC channel activation. FASEB J (2007) 1.77
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.71
STIM protein coupling in the activation of Orai channels. Proc Natl Acad Sci U S A (2009) 1.70
Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.66
Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res (2003) 1.63
Role of STIM and Orai proteins in the store-operated calcium signaling pathway. Cell Calcium (2007) 1.62
Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem (2002) 1.61
Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol (2007) 1.61
STIM and Orai: dynamic intermembrane coupling to control cellular calcium signals. J Biol Chem (2009) 1.59
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res (2006) 1.58
Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs (2002) 1.52
Retracted FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol (2005) 1.51
A functional link between store-operated and TRPC channels revealed by the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2. J Biol Chem (2005) 1.49
Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav (2003) 1.48
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (2010) 1.47
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther (2011) 1.45
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res (2004) 1.41
Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem (2005) 1.41
Blockade of NOX2 and STIM1 signaling limits lipopolysaccharide-induced vascular inflammation. J Clin Invest (2013) 1.40
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol (2006) 1.38
The short N-terminal domains of STIM1 and STIM2 control the activation kinetics of Orai1 channels. J Biol Chem (2009) 1.37
4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem (2002) 1.37
Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem (2004) 1.37
Cerebral angiogenesis and expression of angiogenic factors in aging rats after exercise. Curr Neurovasc Res (2006) 1.36
Antioxidant activity of methanol extracts obtained from Plantago species. J Agric Food Chem (2005) 1.32
Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther (2006) 1.32
Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Stat Med (2003) 1.30
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol (2011) 1.30
Location and function of STIM1 in the activation of Ca2+ entry signals. J Biol Chem (2008) 1.30
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol (2009) 1.29
Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther (2007) 1.28
In vitro cytotoxic activity of Thai medicinal plants used traditionally to treat cancer. J Ethnopharmacol (2004) 1.27
Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models. Biometrics (2002) 1.26
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res (2004) 1.26
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.26
Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res (2003) 1.26
Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways. Cancer Res (2003) 1.26
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.25
Stim, ORAI and TRPC channels in the control of calcium entry signals in smooth muscle. Clin Exp Pharmacol Physiol (2008) 1.25
SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer (2008) 1.23
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res (2006) 1.23
RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol Cancer Ther (2013) 1.21
Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks. Cancer Res (2013) 1.20
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.20
Cardiovascular effects of ginger aqueous extract and its phenolic constituents are mediated through multiple pathways. Vascul Pharmacol (2005) 1.18
A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res (2003) 1.17
IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell (2006) 1.17
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer (2013) 1.16
Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin. J Biol Chem (2002) 1.16
Antibacterial, antioxidant and fibroblast growth stimulation of aqueous extracts of Ficus asperifolia Miq. and Gossypium arboreum L., wound-healing plants of Ghana. J Ethnopharmacol (2008) 1.15
Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.14
Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther (2011) 1.13
Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 1.13
Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2011) 1.13
Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol (2005) 1.12
Screening of Indian medicinal plants for acetylcholinesterase inhibitory activity. Phytother Res (2007) 1.11
The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts. Mol Cell Biol (2009) 1.11
Rhabdomyosarcoma: current challenges and their implications for developing therapies. Cold Spring Harb Perspect Med (2014) 1.10
Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets (2004) 1.10
Negative regulation of ASK1 by p21Cip1 involves a small domain that includes Serine 98 that is phosphorylated by ASK1 in vivo. Mol Cell Biol (2007) 1.09
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 1.08
In vitro inhibitory activities of plants used in Lebanon traditional medicine against angiotensin converting enzyme (ACE) and digestive enzymes related to diabetes. J Ethnopharmacol (2008) 1.07
Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs (2007) 1.06
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.05
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2010) 1.05
Gene disruption of the calcium channel Orai1 results in inhibition of osteoclast and osteoblast differentiation and impairs skeletal development. Lab Invest (2012) 1.04
O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther (2002) 1.04
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol (2006) 1.03
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. Stat Med (2005) 1.03
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2012) 1.03
Inhibition of Ca2+ influx is required for mitochondrial reactive oxygen species-induced endoplasmic reticulum Ca2+ depletion and cell death in leukemia cells. Mol Pharmacol (2006) 1.03